NMTC

NeuroOne Medical Technologies Corporation (NMTC) ESG Analysis Analysis (2026)

Invetso Score: 6.3/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.2 (Moderate)

NMTC’s environmental risk profile is moderate, with a low operational footprint but limited transparency on product lifecycle and supply chain sustainability. The company’s focus on minimally invasive technologies may offer indirect environmental benefits, but disclosure lags best-in-class medtech peers.

Social

Score:

NMTC demonstrates strong social performance, driven by its focus on patient outcomes, high R&D investment, and proactive stakeholder engagement. The company’s technologies address critical health needs and support a culture of innovation and safety.

Governance

Score:

Governance practices at NMTC are moderate, with strengths in financial discipline and regulatory compliance. However, board structure and formal ESG oversight are less developed than at larger, more mature peers.

Overall Score

Score:

NMTC’s ESG profile is moderate overall. The company’s strong social impact and disciplined financial management are offset by limited environmental and governance disclosures. As an early-stage medtech innovator, NMTC’s ESG risks are manageable but transparency and formalization of ESG practices lag best-in-class peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on NeuroOne Medical Technologies Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →